close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

904.35 +1.45 (+0.16%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
News headline image
3 cash-producing stocks walking a fine line
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
Regeneron Pharmaceuticals (NASDAQ:REGN) Looks Undervalued Under the Decent Value Framework ↗
Via Chartmill
News headline image
1 Nasdaq 100 stock on our buy list and 2 facing challenges
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
S&P 500 Unusual Volume Movers for Nov. 2, 2026 ↗
Via Chartmill
Topics Stocks
Stock Market Today: Intel’s Worst Day in Four Decades Drags Chips and the Nasdaq to a Rough October Finish ↗
Via Chartmill
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2026 Earnings Beat Driven by Dupixent Growth ↗
Via Chartmill
Topics Earnings
News headline image
The top 5 analyst questions from Regeneron’s Q3 earnings call
Regeneron's third quarter was marked by strong commercial execution and pipeline momentum, with the company delivering results that topped Wall Street’s reve... 
Via StockStory
Topics Earnings
News headline image
Regeneron: 3 Key Takeaways for Long-Term Investors ↗
An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters. 
Via The Motley Fool
Topics Earnings
News headline image
REGN Q3 deep dive: pipeline progress and core brands drive outperformance
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 36.3% year on year to $5.12 billion. I... 
Via StockStory
S&P 500 Top Movers: Gainers and Losers in Today's US Session ↗
Via Chartmill
Topics Stocks
S&P 500 Top Movers: Gainers and Losers in Today's Session ↗
Via Chartmill
Topics Stocks
News headline image
Regeneron (REGN) stock trades up, here is why
What happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-qua... 
Via StockStory
Topics Artificial Intelligence
News headline image
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company... 
Via MarketBeat
Topics ETFs Earnings
News headline image
Regeneron (REGN) Q3 2026 Earnings Call Transcript ↗
Dupixent, EYLEA HD, and Libtayo hit record sales, fueling record earnings growth. 
Via The Motley Fool
Topics Earnings
S&P 500 Premarket Gainers and Losers on Oct. 30, 2026 ↗
Via Chartmill
Topics Stocks
News headline image
Regeneron (NASDAQ:REGN) surprises with strong Q3 2026, stock soars
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 36.3% year on year to $5.12 billion.... 
Via StockStory
News headline image
What to expect from Regeneron’s (REGN) Q3 earnings
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results tomorrow before market hours. Here’s what investors should know. Regeneron beat a... 
Via StockStory
News headline image
1 safe-and-steady stock with exciting potential and 2 facing headwinds
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi... 
Via StockStory
News headline image
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market ↗
Is this company the biggest dark horse in the chronic weight management space? 
Via The Motley Fool
News headline image
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share ↗
Regeneron's biggest growth driver still has plenty of fuel left in the tank. 
Via The Motley Fool
News headline image
Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and... 
Via StockStory
Topics Artificial Intelligence
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
News headline image
Why Regeneron (REGN) Stock Is Trading Lower Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology all... 
Via StockStory
Which S&P500 stocks are moving on Thursday? ↗
Via Chartmill
News headline image
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,... 
Via MarketBeat
Topics ETFs
News headline image
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
News headline image
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30? ↗
The healthcare company will release its third-quarter results next month. 
Via The Motley Fool
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development... 
Via MarketBeat
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.